Inventiva (NASDAQ:IVA – Get Free Report) is projected to post its Q2 2026 results after the market closes on Friday, September 25th. Analysts expect Inventiva to post earnings of ($0.20) per share and revenue of $6.3470 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, September 28, 2026 at 8:00 AM ET.
Inventiva Stock Down 5.5%
Shares of Inventiva stock opened at $3.45 on Thursday. The firm’s 50-day moving average price is $4.47 and its two-hundred day moving average price is $4.79. Inventiva has a 1-year low of $3.35 and a 1-year high of $7.98.
Analyst Ratings Changes
Several research analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Cantor Fitzgerald assumed coverage on Inventiva in a research report on Friday, July 17th. They issued an “overweight” rating for the company. Piper Sandler reiterated an “overweight” rating on shares of Inventiva in a research report on Wednesday, September 16th. Finally, Guggenheim boosted their price objective on Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, September 15th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $15.75.
Inventiva Company Profile
Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.
Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.
Further Reading
- Five stocks we like better than Inventiva
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.
